Overview

• Pfizer will offer Medicaid most‑favored‑nation pricing and match peer‑country levels on new U.S. drug launches, according to the White House.
• The TrumpRx site will direct patients to manufacturers’ own sales channels with government‑negotiated prices, with a target launch in early 2026.
• Officials and Pfizer said many medicines would see average discounts near 50%, with some listed examples reduced by roughly 80% to 85% on TrumpRx.
• In return, Pfizer receives a three‑year reprieve from planned pharmaceutical tariffs and pledges $70 billion for U.S. manufacturing and R&D.
• Effects on Medicare, commercial insurance, and typical out‑of‑pocket costs remain uncertain, as other drugmakers face an Oct. 1 tariff deadline without similar commitments.